CeriBell (CBLL) Competitors $23.00 -0.25 (-1.05%) As of 03:57 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsTrends CBLL vs. NVCR, LIVN, ENOV, WRBY, TNDM, LMAT, CNMD, SLNO, TMDX, and CDREShould you be buying CeriBell stock or one of its competitors? The main competitors of CeriBell include NovoCure (NVCR), LivaNova (LIVN), Enovis (ENOV), Warby Parker (WRBY), Tandem Diabetes Care (TNDM), LeMaitre Vascular (LMAT), CONMED (CNMD), Soleno Therapeutics (SLNO), TransMedics Group (TMDX), and Cadre (CDRE). These companies are all part of the "medical equipment" industry. CeriBell vs. NovoCure LivaNova Enovis Warby Parker Tandem Diabetes Care LeMaitre Vascular CONMED Soleno Therapeutics TransMedics Group Cadre CeriBell (NASDAQ:CBLL) and NovoCure (NASDAQ:NVCR) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, risk, valuation, profitability, dividends, earnings, community ranking and media sentiment. Does the MarketBeat Community prefer CBLL or NVCR? NovoCure received 469 more outperform votes than CeriBell when rated by MarketBeat users. However, 100.00% of users gave CeriBell an outperform vote while only 63.68% of users gave NovoCure an outperform vote. CompanyUnderperformOutperformCeriBellOutperform Votes8100.00% Underperform VotesNo VotesNovoCureOutperform Votes47763.68% Underperform Votes27236.32% Does the media favor CBLL or NVCR? In the previous week, NovoCure had 16 more articles in the media than CeriBell. MarketBeat recorded 19 mentions for NovoCure and 3 mentions for CeriBell. NovoCure's average media sentiment score of 0.73 beat CeriBell's score of 0.45 indicating that NovoCure is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CeriBell 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral NovoCure 3 Very Positive mention(s) 0 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals and insiders believe in CBLL or NVCR? 84.6% of NovoCure shares are held by institutional investors. 6.3% of NovoCure shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Do analysts rate CBLL or NVCR? CeriBell currently has a consensus price target of $32.60, indicating a potential upside of 40.28%. NovoCure has a consensus price target of $32.67, indicating a potential upside of 21.75%. Given CeriBell's stronger consensus rating and higher possible upside, analysts plainly believe CeriBell is more favorable than NovoCure.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CeriBell 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00NovoCure 0 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.67 Is CBLL or NVCR more profitable? CeriBell has a net margin of 0.00% compared to NovoCure's net margin of -25.93%. CeriBell's return on equity of 0.00% beat NovoCure's return on equity.Company Net Margins Return on Equity Return on Assets CeriBellN/A N/A N/A NovoCure -25.93%-41.48%-12.74% Which has higher earnings & valuation, CBLL or NVCR? CeriBell has higher earnings, but lower revenue than NovoCure. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCeriBellN/AN/AN/AN/AN/ANovoCure$509.34M5.70-$207.04M-$1.40-19.16 SummaryCeriBell beats NovoCure on 7 of the 13 factors compared between the two stocks. Get CeriBell News Delivered to You Automatically Sign up to receive the latest news and ratings for CBLL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CBLL vs. The Competition Export to ExcelMetricCeriBellElectromedical equipment IndustryMedical SectorNASDAQ ExchangeMarket Cap$832.46M$3.54B$5.38B$9.23BDividend YieldN/A1.66%5.37%3.99%P/E RatioN/A19.0386.8317.27Price / SalesN/A70.791,202.5482.39Price / CashN/A37.3043.6036.97Price / BookN/A3.955.004.72Net IncomeN/A$94.49M$117.81M$224.61M7 Day Performance15.33%1.71%2.06%1.41%1 Month Performance-13.02%3.62%3.44%4.13%1 Year PerformanceN/A5.12%25.50%21.37% CeriBell Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CBLLCeriBellN/A$23.00-1.1%$32.60+41.8%N/A$823.36MN/A0.00N/AGap DownNVCRNovoCure3.1357 of 5 stars$26.17+0.6%$32.67+24.8%+84.3%$2.83B$509.34M-18.691,453LIVNLivaNova3.4886 of 5 stars$48.30+0.7%$69.17+43.2%-4.2%$2.62B$1.15B115.002,900Analyst DowngradeNews CoverageENOVEnovis3.1027 of 5 stars$46.68+2.7%$67.00+43.5%-21.9%$2.61B$1.71B-21.326,550WRBYWarby Parker2.2692 of 5 stars$24.57-6.3%$20.92-14.9%+88.5%$2.50B$669.77M-90.983,491Analyst ForecastNews CoverageTNDMTandem Diabetes Care4.5056 of 5 stars$35.15-6.3%$53.81+53.1%+44.2%$2.31B$747.72M-18.212,400News CoveragePositive NewsLMATLeMaitre Vascular2.9188 of 5 stars$99.06+0.8%$94.57-4.5%+66.5%$2.23B$193.48M54.13490Analyst RevisionPositive NewsCNMDCONMED4.7775 of 5 stars$67.75+1.3%$79.80+17.8%-28.9%$2.09B$1.24B16.094,000Positive NewsSLNOSoleno Therapeutics4.3557 of 5 stars$46.88+1.9%$74.83+59.6%+0.9%$2.02BN/A-14.1230Analyst RevisionPositive NewsTMDXTransMedics Group4.2139 of 5 stars$57.20-1.4%$122.70+114.5%-29.7%$1.92B$241.62M60.85210CDRECadre2.4682 of 5 stars$38.23+6.1%$39.75+4.0%+19.7%$1.55B$482.53M46.062,435Dividend IncreaseAnalyst RevisionNews Coverage Related Companies and Tools Related Companies NovoCure Alternatives LivaNova Alternatives Enovis Alternatives Warby Parker Alternatives Tandem Diabetes Care Alternatives LeMaitre Vascular Alternatives CONMED Alternatives Soleno Therapeutics Alternatives TransMedics Group Alternatives Cadre Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CBLL) was last updated on 1/23/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | SponsoredTrump’s Inauguration Shocker: “Move Your Cash Now”Just in the first week after Trump's win, many stocks jumped by double and even triple digits. But now he's...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CeriBell Please log in to your account or sign up in order to add this asset to your watchlist. Share CeriBell With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
